ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 2 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Results 21 - 22 of 22 : « Previous 1 2

Recs

0
Member Avatar sailor175 (33.26) Submitted: 9/22/2006 11:41:41 PM : Outperform Start Price: $4.25 ARQL Score: +32.40

I am loosing money here.
hope this intersting new technology will kill cancer and restore cells not just due to my investment but for millions a better life of people.
very very very speculative

Report this Post Reply | Reply | Permalink

Recs

0
Member Avatar RBBioContest06 (54.27) Submitted: 5/31/2006 10:43:41 PM : Outperform Start Price: $5.38 ARQL Score: -1.92

Picked by Encore7148

Report this Post Reply | Reply | Permalink
Results 21 - 22 of 22 : « Previous 1 2

Featured Broker Partners


Advertisement